Abstract: Abstract‐We have previously described a 5‐fluorodeox yuridine (FUdR) resistant neuroblastoma variant, possessing normal levels of ATP: thymidine‐5‐phosphotransferase (EC 18.104.22.168) [trivial name: thymidine kinase (TK)] but an 8‐fold elevation in methy1enetetrahydrofolate:dUrd‐5′P C‐methyltransferase (EC 2.l.l.b) [trivial name: thymidylate synthetase (TS)] relative to the drug‐sensitive parental clone. This variant possesses elevated levels of the parental TS species, 30% of which is uninhibitable by in vivo pulses of FUdR, suggesting the subcellular compartmentalization of this enzyme. We contrast this variant with a second FUdR resistant clone isolated from an ethyl‐methane‐sulfonate mutagenized population of the parental clone. This variant displays a 96% reduction in TK specific activity, despite normal FUdR and thymidine uptake rates, demonstrating the independence of thymidine phosphorylation and uptake. Grown without drug, its resistance declines (half‐life of 15 cell divisions) with its TK specific activity rising to a plateau of 16% of the parental level after 56 cell divisions. Thymidine (1.0μM) protects the TK+ but not the TK‐ variants from FUdR induced growth inhibition but is without effect on TS specific activity. Unlike Tetrahymena (DICKENS et al., 1975), neuroblastoma TS activities appear not to be regulated by adenosine or guanosine cyclic nucleotide levels.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Neurochemistry|
|State||Published - Dec 1977|
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience